Search Results

You are looking at 1 - 10 of 20 items for :

  • "everolimus" x
Clear All
Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

). MTTs with the MTOR inhibitor everolimus and the receptor tyrosine kinase (RTK) inhibitor sunitinib have been approved in clinical practice for locally advanced and metastatic pancreatic NENs (PanNENs) ( 2 , 3 ). In addition, everolimus has been shown

Open access

Maria Cristina De Martino, Richard A Feelders, Claudia Pivonello, Chiara Simeoli, Fortuna Papa, Annamaria Colao, Rosario Pivonello and Leo J Hofland

cytosketeton function and seems to be involved in the activation of AKT function ( 10 , 11 ). Several drugs inhibiting the mTORC1 complex have been developed as anticancer treatment including sirolimus, temsirolimus and everolimus (traditional mTOR inhibitors

Open access

E T Aristizabal Prada and C J Auernhammer

disease of NETs of the GEP system ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ), including molecular targeted therapy with the mammalian target of rapamycin (mTOR) inhibitor everolimus and the multi-tyrosinkinase inhibitor sunitinib, has significantly progressed

Open access

Giulia Bresciani, Angeliki Ditsiou, Chiara Cilibrasi, Viviana Vella, Federico Rea, Marco Schiavon, Narciso Giorgio Cavallesco, Georgios Giamas, Maria Chiara Zatelli and Teresa Gagliano

( 1 , 15 ). Everolimus and sunitinib are two targeted agents approved by the Food and Drugs Administration (FDA) for the treatment of different types of NENs ( 16 ). Everolimus is an mTOR inhibitor capable to slow down the tumour growth and arrest

Open access

Kjell Oberg, Eric Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Margot Tesselaar, Valentina Ambrosini, Richard P Baum, Matthew Kulke, Marianne Pavel, Jaroslaw Cwikla, Ignat Drozdov, Massimo Falconi, Nicola Fazio, Andrea Frilling, Robert Jensen, Klaus Koopmans, Tiny Korse, Dik Kwekkeboom, Helmut Maecke, Giovanni Paganelli, Ramon Salazar, Stefano Severi, Jonathan Strosberg, Vikas Prasad, Aldo Scarpa, Ashley Grossman, Annemeik Walenkamp, Mauro Cives, Irene Virgolini, Andreas Kjaer and Irvin M Modlin

anti-proliferative agents in patients with significant metastatic burden, e.g., >50% neuroendocrine tumor liver metastases (NELM) and/or extra-hepatic metastases. The panel was unsure whether everolimus had a role in non-pancreatic NEN disease (it

Open access

Xu Han, Xuefeng Xu, Hongyun Ma, Yuan Ji, Dansong Wang, Tiantao Kuang, Wenchuan Wu, Bin Song, Gang Li, Gang Jin and Wenhui Lou

patients had received hepatic arterial chemoembolization (HACE), four patients had received radiofrequency ablation (RFA), five patients had received Octreotide LAR, three patients had received sunitinib, one patient had received everolimus, seven patients

Open access

Michael Ulm, Arvind V Ramesh, Keely M McNamara, Suriyan Ponnusamy, Hironobu Sasano and Ramesh Narayanan

halted. Everolimus is a mammalian target of rapamycin (mTOR) inhibitor that has completed phase II clinical trials ( 45 ). In a phase II clinical trial, everolimus combined with bicalutamide has been administered orally to patients with progressive mCRPC

Open access

Anna Malczewska, Magdalena Witkowska, Karolina Makulik, Agnes Bocian, Agata Walter, Joanna Pilch-Kowalczyk, Wojciech Zajęcki, Lisa Bodei, Kjell Oberg and Beata Kos-Kudła

23 25 Image-negative (dual modality)  Number 8 3 N/A Disease status (RECIST 1.1)  Stable 34 30 N/A  Progressive 8 3 Current treatment  SSA 27 27 N/A  Everolimus 1 3

Open access

Benjamin G Challis, Andrew S Powlson, Ruth T Casey, Carla Pearson, Brian Y Lam, Marcella Ma, Deborah Pitfield, Giles S H Yeo, Edmund Godfrey, Heok K Cheow, V Krishna Chatterjee, Nicholas R Carroll, Ashley Shaw, John R Buscombe and Helen L Simpson

-regulatory hormones ( 22 ). Abolition of hypoglycaemia and tumour regression has been reported with everolimus ( 5 , 23 ) and this agent is recommended for use in malignant insulinoma resistant to standard medical therapy ( 24 ). Adverse effects are common, however

Open access

Samira M Sadowski, Emanuel Christ, Benoit Bédat, Attila Kollár, Wolfram Karenovics, Aurel Perren, Frédéric Triponez and on behalf of the SwissNET registry

6 patients of the studied cohort, making analyses and recommendations based on our study impossible. Very recent evidence suggests that everolimus has a beneficial effect on progression-free survival in patients with lung carcinoids ( 19 ). This